AstraZeneca, a major British pharmaceutical company, has announced provisional results that it was 79% effective in clinical trials conducted in the United States and other countries for the new coronavirus vaccine.

AstraZeneca is conducting final-stage clinical trials in the United States, Chile, and Peru for a new coronavirus vaccine that is being inoculated in the United Kingdom and other countries, and announced preliminary analysis results on the 22nd.



According to the results, of the 32,449 people in the clinical trial, 141 cases were confirmed to have symptoms of the new coronavirus.



As a result of comparing and analyzing those who actually received the vaccine and those who did not, the effectiveness of preventing the onset of the new coronavirus was 79%.



No one was seriously ill.



Approximately 20% of participants in clinical trials are 65 years of age or older, and the effectiveness of preventing the onset was 80% in this age group.



Regarding this vaccine, there have been cases where blood clots were confirmed after vaccination, and in some countries such as Europe, there have been a series of movements to temporarily suspend vaccination as a preventive measure, but EMA has been conducting detailed investigations. = The European Medicines Agency announced on the 18th that it is safe, and France and Germany have resumed vaccination.



As a result of verifying the data of this clinical trial by an independent institution, it was not confirmed that the risk of developing thrombosis etc. increased after at least one inoculation.



AstraZeneca will soon apply for an emergency use authorization from the US FDA = Food and Drug Administration.